CRN announces new chairman and 2017 board of directors

Chairman names officers and committee chairs

The Council for Responsible Nutrition (CRN), the leading trade association for the dietary supplement and functional food industry, is pleased to announce that Jim Hyde, Vice President and General Manager at Balchem Human Nutrition and Pharma, has been elected chair of the association’s board of directors.

He has served on CRN’s Executive Committee for the last 5 years.

Mr Hyde will hold the chairman position through 2018, succeeding Harvey Kamil, Vice Chairman of The Nature’s Bounty Company. Mr Kamil will continue to serve on the board as immediate past chair.

Mr Hyde has 20 years of experience in the dietary supplement industry.

He served as the CEO of Albion Laboratories for 16 years until Albion was acquired by Balchem Corporation in February 2016, at which point he assumed his current position with Balchem.

You may also like

Research & Development

CRN responds to JAMA Cardiology report on fish oil health claims

Following the release of the JAMA Cardiology report that was released last week, trade association CRN has given a response and noted a lack of scientific evidence
Regulatory

CRN urges FDA to reconsider “food groups-only” approach

CRN’s comments to FDA emphasised the value of including dietary supplements and functional foods
Ingredients

New Mind the Gap resource focuses on threat to eye health from blue light

Blue light – and the serious harm it can do to eye health – is the subject of IADSA’s latest Mind the Gap resource
Ingredients

CRN and IPA release best practice guidelines for probiotics

The Council for Responsible Nutrition (CRN) and the International Probiotics Association (IPA) have released voluntary guidelines for labeling of probiotics in supplements, foods and beverages
Ingredients

GOED and CRN publish oxidation white paper

The white paper was written to help improve industry knowledge about oxidation testing protocols and potential issues with oxidised oils
Finance

Overcoming the dairy dilemma: Valio sees an increase in net sales

With many hurdles to overcome, Valio's net profits grew from 2022 by 2%
Ingredients

dsm-firmenich and Lallemand partner to launch early life synbiotic solutions

The solution will contain a combination of human milk oligosaccharides (HMOs) that will mimic breast milk, boosting the infant immune system and gut microbiome
Subscribe now